Table 3.
Diagnostic accuracy of CSF biomarkers at baseline.
| Controls vs. AD |
Controls vs. pMCI |
Controls vs. sMCI |
sMCI vs. AD |
pMCI vs. AD |
sMCI vs. pMCI |
|
|---|---|---|---|---|---|---|
| Aβ43 | AUC: 0.97 Sens: 93 Spec: 96 |
AUC: 0.93 Sens: 90 Spec: 100 |
AUC: 0.75 Sens: 53 Spec: 100 |
AUC: 0.73 Sens: 86 Spec: 68 |
AUC: n.s. |
AUC: 0.71 Sens: 80 Spec: 68 |
| Aβ42 | AUC: 0.96 Sens: 86 Spec: 96 |
AUC: 0.94 Sens: 85 Spec: 96 |
AUC: 0.81 Sens: 63 Spec: 92 |
AUC: n.s. |
AUC: n.s. |
AUC: n.s. |
| t-tau/Aβ43 | AUC: 0.94 Sens: 93 Spec: 91 |
AUC: 0.91 Sens: 90 Spec: 96 |
AUC: 0.72 Sens: 58 Spec: 91 |
AUC: 0.83 Sens: 79 Spec: 90 |
AUC: n.s. |
AUC: 0.81∗ Sens: 75 Spec: 90 |
| t-tau/Aβ42 | AUC: 0.95 Sens: 86 Spec: 96 |
AUC: 0.91 Sens: 90 Spec: 96 |
AUC: 0.78 Sens: 74 Spec: 87 |
AUC: 0.78 Sens: 64 Spec: 90 |
AUC: n.s. |
AUC: 0.72∗ Sens: 85 Spec: 63 |
∗For comparison of sMCI vs. pMCI subgroups, the AUC of the t-tau/Aβ43-ratio is larger than the AUC of the t-tau/Aβ42-ratio (p = 0.040, DeLong method). AD, Alzheimer’s disease; pMCI, patients with mild cognitive impairment that progressed to AD over 2 years; sMCI, patients with mild cognitive impairment that did not progress to AD over 2 years; Aβ43, amyloid beta 1–43; Aβ42, amyloid beta 1–42; t-tau, total tau; AUC, area under the ROC curve; Sens, sensitivity (%); Spec, specificity (%); n.s., not significant.